Menopause Hormone Therapy Current Evidence and Clinical Use: (IGWHC) - Lupine Publishers

Menopause Hormone Therapy Current Evidence and Clinical Use by BaquedanoL, LaprestaM and Colmenarejo F in Interventions in Gynaecology and Women’s Healthcare (IGWHC) in Lupine Publishers

Spontaneous menopause, the permanent cessation of menstruation caused by loss of ovarian function, occurs at a mean age of 51-52 years. As life expectancy increases,women are living far longer after menopauseonset than in the past.Climacteric syndrome is common but it is not always necessary to treat women in the transition and in menopause. However, hormonal changes can be associated with symptoms; the most common are hot flashes and night sweats. Others like dyspareunia, vaginal dryness, mood swings and sexual dysfunction can frequently appear. There is an increase in bone resorption on occasions leading toosteopenia and osteoporosis. Women who are severely symptomatic, 25-30% of all menopause women, have their quality of life affected [1]. In addition to this deleterious effect, menopausal womenalso have an increased prevalence of coronary heart disease and obesity [2].Menopause hormone therapy (MHT) is the most effective treatment for symptoms. It is the gold standard for relievingvasomotorsymptoms (VSM) and also it improves other problems related with menopause. Furthermore, MHT is effective in preventing the loss of bone massand in reducing cardiovascular accident [3]. Thus, there is a global consensus statement on MHT that concluded that for symptomatic women the benefits are higher than risks before 60 years old or within 10 years after menopause [4-6].

http://www.lupinepublishers.com/igwhc/abstracts/IGWHC.MS.ID.000134.php
http://www.lupinepublishers.com/igwhc/fulltext/IGWHC.MS.ID.000134.php
http://www.lupinepublishers.com/igwhc/pdf/IGWHC.MS.ID.000134.pdf